Description of medicine: Disodium salt of ethylenediaminetetraacetic acid (Dinatrii aethylendiamintetraacetas)
Disodium Salt of Ethylenediaminetetraacetic Acid (Dinatrii aethylendiamintetraacetas).
Synonyms: Trilon B, EDTU, Calsol, Dinatriumedetat, Endrate, Irgalon, Kalex, Prochelate, Questrex, Sequestrene, Sequestrol, Sodium edetate, Tetracemindinatriumi, Titriplex, Trilon B, Tyclarosol, Versene, etc.
White crystalline powder, soluble in water, practically insoluble in alcohol and ether.
Disodium salt of EDTU (Na 2 EDTU) belongs, as well as tetacin-calcium and pentacin, to the group of complexones.
It is able to form complex compounds with various cations, including calcium ions. This makes it possible to use EDTA for diseases accompanied by excessive deposition of calcium salts in the body, with pathological ossification of the skeleton, arthritis with deposition of salts, calcium deposition in muscles, kidneys, vein walls, scleroderma, etc. Sometimes they are used to treat some forms of ectopic arrhythmias, especially arising in connection with an overdose of cardiac glycosides.
When used for medicinal purposes, it must be borne in mind that the therapeutic effect without side effects occurs when the drug is slowly introduced into the blood stream; under these conditions, interaction with serum calcium occurs slowly and the serum calcium content does not significantly decrease, since the loss is compensated by mobilizing calcium from tissues, in particular from bone tissue, and excess deposits in organs. With the rapid administration of the drug, physiological mechanisms do not have time to eliminate a decrease in serum calcium levels and acute tetany may develop.
EDTU, in connection with the ability to bind calcium ions, is also used as an anticoagulant in the preservation of blood.
The main indications for the use of EDTU are diseases with the phenomena of calcification: dermatomyositis, scleroderma, ossifying myositis.
For therapeutic purposes, a solution of EDTU is administered intravenously. Dilute 5% solution of EDTA in isotonic sodium chloride solution or 5% glucose solution.
Enter at a rate of 8 to 12 drops per minute. Adults and children over 10 years of age are injected with 10 ml of a 5% solution of EDTA diluted in 200 ml of solvent; children under 10 years old - 5 ml of a 5% solution of EDTA diluted in 100 ml of solvent.
The course of treatment consists of 15 injections: administered in cycles of 5 days daily with 7-day breaks (3 cycles per course). The courses of treatment are repeated after 4 to 6 months.
During treatment, it is necessary to monitor the content of calcium and phosphorus in the blood and daily urine. Diet during treatment should contain a reduced amount of calcium.
When the drug is injected into a vein, a burning sensation is sometimes felt, which can spread throughout the body and persist for 1 to 2 hours after the end of the infusion.
With rapid administration, tetany may develop; in these cases, it is necessary to stop the administration of the drug.
EDTU is contraindicated in hemophilia, decreased blood coagulation, hypocalcemia, kidney and liver diseases.
Release form: 5% solution in ampoules of 5 or 10 ml (Solutio Dinatrii atylendiamintetraacetatis 5% PPO injectionibus) in a package of 10 ampoules.
Storage: List B.